197 related articles for article (PubMed ID: 31474796)
1. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials.
Agrawal R; Majeed M; Attar BM; Omar YA; Mbachi C; Wang Y; Flores E; Shaqib S; Wang Y; Udechukwu V; Demetria M; Gandhi S
Ann Gastroenterol; 2019; 32(5):489-497. PubMed ID: 31474796
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo NS; Sultan S; Reynolds JM; Levy C
Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis.
Zhang Y; Chen K; Dai W; Xia Y; Wang F; Shen M; Cheng P; Wang C; Yang J; Zhu R; Zhang H; Li J; Zheng Y; Wang J; Lu J; Zhou Y; Guo C
Hepatol Res; 2015 Jan; 45(1):48-58. PubMed ID: 24934524
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.
Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J
Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.
Yin Q; Li J; Xia Y; Zhang R; Wang J; Lu W; Zhou Y; Zheng Y; Abudumijiti H; Chen R; Chen K; Li S; Liu T; Wang F; Lu J; Zhou Y; Guo C
Drug Des Devel Ther; 2015; 9():5407-19. PubMed ID: 26491252
[TBL] [Abstract][Full Text] [Related]
7. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
Zhang Y; Li S; He L; Wang F; Chen K; Li J; Liu T; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Xia Y; Zhou Y; Lu J; Guo C
Drug Des Devel Ther; 2015; 9():2757-66. PubMed ID: 26045661
[TBL] [Abstract][Full Text] [Related]
9. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].
Feng BL; Yu HH; Shen W
Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343
[No Abstract] [Full Text] [Related]
10. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
11. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
[TBL] [Abstract][Full Text] [Related]
12. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.
Lin W; Wang JX; Liu YJ
Syst Rev; 2024 Jan; 13(1):46. PubMed ID: 38287391
[TBL] [Abstract][Full Text] [Related]
13. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
Yagi M; Matsumoto K; Komori A; Abe M; Hashimoto N; Inao M; Namisaki T; Kawata K; Ninomiya M; Fujii H; Takahashi A; Kang JH; Takamura M; Arakawa M; Joshita S; Sato K; Itakura J; Nomura T; Kakisaka K; Kaneko A; Tamura Y; Miura R; Aiso M; Arizumi T; Asaoka Y; Kikuchi K; Takikawa Y; Masaki T; Umemura T; Honda A; Ohira H; Kawada N; Yoshiji H; Mochida S; Takikawa H; Tanaka A;
Liver Int; 2020 Aug; 40(8):1926-1933. PubMed ID: 32438508
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study.
Iwasaki S; Ohira H; Nishiguchi S; Zeniya M; Kaneko S; Onji M; Ishibashi H; Sakaida I; Kuriyama S; Ichida T; Onishi S; Toda G;
Hepatol Res; 2008 Jun; 38(6):557-64. PubMed ID: 18452482
[TBL] [Abstract][Full Text] [Related]
15. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.
Itakura J; Izumi N; Nishimura Y; Inoue K; Ueda K; Nakanishi H; Tsuchiya K; Hamano K; Asahina Y; Kurosaki M; Uchihara M; Miyake S
Hepatol Res; 2004 Aug; 29(4):216-222. PubMed ID: 15288014
[TBL] [Abstract][Full Text] [Related]
17. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis.
Joshita S; Umemura T; Yamashita Y; Sugiura A; Yamazaki T; Fujimori N; Matsumoto A; Tanaka E
Hepatol Res; 2019 Oct; 49(10):1236-1243. PubMed ID: 31077509
[TBL] [Abstract][Full Text] [Related]
19. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
20. Primary biliary cholangitis: treatment.
Cazzagon N; Floreani A
Curr Opin Gastroenterol; 2021 Mar; 37(2):99-104. PubMed ID: 33492001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
